Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 261

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

Psychedelic Culture 2026

TRYP EXPO

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

MindMed Announces the Approval of Mescaline Study

Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development,...

Webinar with Tim Cools of Psychedelic Experience

Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged...

What Is Sacred Reciprocity?

Mydecine Provides Update on Spin-Out of U.S. Cannabis Assets

MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston...

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

The Chopra Foundation and MindMed Enter Into Letter of Intent to...

Cybin Granted IRB Approval for Phase II Clinical Trials of its...

Load more

EDITOR PICKS

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

Psychedelic Culture 2026

TRYP EXPO

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©